Objective: We prospectively analyzed the dose dependent outcome and side eects of neurogenic bladder patients with intravesical application of oxybutynin at our centre. Materials and methods: We examined the data of 32 patients with neurogenic bladders and detrusor hyperre¯exia. We registered clinical outcome, continence situation, side eects and urodynamic data of patients with (A) standard dosages of intravesical oxybutynin (0.3 mg/kg bodyweight per day) and (B) with increasing dosages in steps of 0.2 mg/kg bodyweight per day up to 0.9 mg/kg bodyweight per day. Results: We examined 32 patients aged 1 to 34 years, mean age 12 years. 21/32 patients became totally continent with the dosage (A). They showed a signi®cant (P50.01) decrease in the median max detrusor pressure (MDP) and a signi®cant (P50.01) increase in the median compliance and the median age adjusted bladder capacity (AABC). Eleven out of 32 patients remained incontinent under this dosage (A). Their median MDP, their median compliance and their median AABC remained nearly unchanged. Seven out of 11 incontinent patients under dosage (A) were treated eciently with the higher dosages (B). Their median necessary dosage escalation to achieve treatment success was 0.7 mg/kg bodyweight per day (range 0.5 to 0.9 mg/kg bodyweight per day). Their median MDP was signi®cantly (P50.05) decreased and their median compliance and median AABC were signi®cantly (P50.05) increased. Four out of 11 patients remained incontinent and showed only little improvement in urodynamic data. Two out of 11 patients with the dosage escalation (B) showed side eects at a dosage of 0.9 mg/kg bodyweight per day. Conclusions: The intravesical application of oxybutynin was a well tolerated and ecacious therapy. The topical oxybutynin therapy dosage (A) was ecient in 66% of our selected patients, the escalating dosage titration (B) could increase the eciency to 87%. Spinal Cord (2000) 38, 250 ± 254
Introduction
The clinical management of neurogenic bladder dysfunction has dramatically improved since Guttmann et al 1 and Lapides et al 2 introduced the intermittent catheterization. McGuire et al 3 recognized in 1981 that low storage pressures of the bladder protected the upper urinary tract from the major cause of morbidity and mortality in these patients, the renal function deterioration caused by hydronephrosis and pyelonephritis. 4 Today, the standard treatment for neurogenic hyperre¯exic bladders consists of clean intermittent catheterization combined with anticholinergic medication. Intermittent catheterization increases the eective bladder capacity by decreasing the residual urine and prevents high voiding pressures. Anticholinergics provide a bladder acting as a low pressure urinary reservoir and prevent urinary incontinence by relaxation of the hyperre¯exic detrusor. 5 Of the anticholinergic agents that are currently available oxybutynin hydrochloride is most commonly used. It is a tertiary amine with neurotropic especially antimuscarinic and anticholinergic as well as myotropic, antispasmodic and local anesthetic action. 6 The clinical ecacy of oral oxybutynin in the treatment of detrusor hyperre¯exia is demonstrated in several randomized, controlled, double-blind trials. Moisey et al 7 for example found an improvement of symptoms in 69% of their patients. In a randomized double-blind multi-center trial ThuÈ ro et al 8 oxybutynin (about 58%) than with propantheline (about 44%) and placebo (43%).
Several side eects have been described with oral oxybutynin: dryness of the mouth, constipation, diarrhea, cardiac arrhythmias, vision disturbances, gastric distress, nausea, headache, hot¯ushes, tinnitus and fatigue.
A dierent form of application, the intravesical application of oxybutynin is used in neurogenic bladder patients who remain incontinent on oral anticholinergic medication or do not tolerate this oral medication due to the side eects described before. 6, 9 In most reports intravesical oxybutynin is used in dosages between 0.2 and 0.4 mg/kg bodyweight per day. 5, 10 To the best of our knowledge no higher dosages have been reported in the literature. However, the ecacy of this therapy and the side eects remain unclear in the literature. Brendler et al 6 and Green®eld et al 11 found an improvement in continence rate in more than 80% of their patients and no side eects of the intravesical therapy. Kaplinsky et al 12 could only ®nd an improvement in continence rate in 61% of their patients and found intolerable side eects in 25% of their patients. Therefore the aim of our prospective analysis was to evaluate the ecacy and the side eects of a standard dosage of intravesical oxybutynin (0.3 mg/kg bodyweight per day) and the eects of an increasing intravesical dosage (0.5 to 0.9 mg/kg bodyweight per day) in neurogenic hyperre¯exic bladder patients.
Materials and methods

Inclusion criteria
All patients included in this cohort study had to have neurogenic bladders with detrusor hyperre¯exia. Indications for intravesical therapy included inadequate therapeutic response on oral anticholinergic medication (n=15 patients) and/or intolerable side eects from the oral formulation (n=13 patients), and diculty in swallowing of the oxybutynin tablets in young children (n=4 patients).
Exclusion criteria
All patients with the suspicion of external sphincter insuciency and an abdominal leak point pressure less than 40 cmH 2 O were excluded from the study. Patients with oral anticholinergic, antispasmodic and sympathomimetic medication were also excluded.
Aim of treatment
The primary goal of treatment was to achieve continence during day and night time. A secondary goal was videourodynamically proven success criteria, de®ned as:
(1) age adjusted bladder capacity greater than 70% (2) compliance 15 ml/cmH 2 O or more (3) maximal detrusor pressure less than 40 cmH 2 O.
Trial protocol
All patients performed intermittent catheterization ®ve times daily. They all had a pre-treatment videourodynamic evaluation. Treatment started with a standard dosage (A) of 0.3 mg/kg bodyweight per day (0.3 mg/ kg BWd), divided into three portions instilled every 8 h. Videourodynamic studies were repeated 2 ± 4 weeks after beginning of intravesical oxybutynin therapy. In patients where the dosage (A) failed to reach total continence and treatment success criteria the dosage (B) was increased in steps of 0.2 mg/kg bodyweight per day up to a maximum dosage of 0.9 mg/kg bodyweight per day if necessary. Two to four weeks after each dosage increase, treatment eect was evaluated videourodynamically. Dosage increase was stopped when continence and treatment success criteria were reached. For the intravesical application, commercially available 5 mg oxybutynin powder was dissolved in 15 ml sterile isotonic sodium chloride solution. The dose of the solution, adjusted to the patients' bodyweight, was instilled into the bladder through the catheter used for regular intermittent catheterization. The catheter was then¯ushed with 5 ml isotone sodium chloride solution to ensure delivery of the full dose and it was removed afterwards. The solution remained intravesically until the bladder was next emptied by catheterization.
Patients or parents maintained a detailed sheet of drug administration, of incontinence periods, of side eects during intravesical therapy and urine output by volume charts.
Videourodynamic studies were performed according to ICS criteria. 13 All studies were done in the mornings after the ®rst intravesical application with the oxybutynin in the bladder until the beginning of the videourodynamic evaluation. A MMS 2000 urodynamic system (Innocept 1 , Gladbeck, Germany) was used with the patient in supine position. Radiopaque material (378C) was infused into the bladder through a 6F or 9F double lumen urethral catheter (RuÈ sch 1 , Bo È blingen, Germany). A 6F catheter was used in patients up to 10 years of age, a 9F catheter in patients older than 10 years. The infusion rate was between 2 and 20 ml/min depending on the patients age. The bladder ®lling was stopped when the age expected bladder capacity was reached to avoid bladder overdistension. Maximal detrusor pressure, total bladder capacity and detrusor compliance were evaluated.
Included patients
Since 1995, 32 incontinent patients with neurogenic hyperre¯exic bladders, 18 male and 14 female with a mean age of 12 years (range 1 ± 34 years), were Dosage escalation of oxybutymin A Haferkamp et al treated with intravesical application of oxybutynin at our department. They consist of 10 tetraplegic and 22 paraplegic patients. Seventeen patients had a spinal cord injury, and 15 were meningomyelocele patients.
De®nitions and statistical analysis
The total bladder capacity evaluated by videourodynamic study is dependent on age. A comparison of capacities of patients with dierent ages is only possible, when an age independent value can be de®ned. Therefore we de®ned the age adjusted capacity using the formula: Age adjusted capacity=(actual videourodynamic capacity/age expected capacity)6100. According to Berger and associates the age expected capacity was calculated for patients of less than 12 years using the formula: Age expected capacity=(age in years+2)630 ml.
14 For patients over 12 years of age, expected capacity was estimated at 500 ml.
Statistical analysis was performed on all data using the Wilcoxon range sum test. 15 The level of signi®cance was preset to P50.05. Statistical software was used: Statistical Analysing System (SAS), Version 6.04. 16 
Results
Thirty-two patients with neurogenic bladders were treated with intravesical oxybutynin. A summary of our patients' data is shown in Tables 1 ± 4 .
Continence Without anticholinergic medication all 32 patients were incontinent during the day and night-time. All patients used diapers. Using intravesical oxybutynin in a standard dosage (A), 21 patients became totally continent. The remaining 11 patients were incontinent, nine during the day and night-time, and two only during night-time. Using increased dosage titration (B) up to maximal 0.9 mg/kg bodyweight per day, seven of these 11 patients became totally continent, four patients remained incontinent during the day and night-time. The median increased dosage to achieve total continence in these seven patients was 0.7 mg/kg bodyweight per day.
Videourodynamic data
Without anticholinergic medication the median age adjusted bladder capacity and the median compliance was reduced, the median maximal detrusor pressure was increased. Median age adjusted bladder capacity and median compliance could be increased signi®cantly (P50.01), median maximal detrusor pressure could be decreased signi®cantly (P50.01) using a standard dosage of intravesical oxybutynin (A). Dividing the patients in a group who became totally continent using the standard dosage (A) and in a group with persisting incontinence we obtained the following results: the 21 continent patients ful®lled all treatment success criteria, the 11 patients who remained incontinent on dosage (A) showed nearly no change in median age adjusted bladder capacity, median compliance and median maximal detrusor pressure. These 11 patients were treated with the increased dosage titration (B). An additional signi®cant increase (P50.05) of median age adjusted bladder capacity and median compliance and a signi®cant decrease (P50.05) of median maximal detrusor pressure could be achieved. Dividing these 11 patients into a group who became totally continent using the dosage escalation (B) and a group with persisting incontinence we obtained the following results: seven continent patients reached all treatment success criteria and four incontinent patients showed a slight increase in median age adjusted bladder capacity and median compliance and a slight decrease of median maximal detrusor pressure, but did not reach the prede®ned treatment success criteria. These four patients underwent surgery. Three patients underwent ileocystoplasty and one patient underwent external sphincterotomy. In ®ve out of seven patients, who had been successfully treated with escalating dosage titration (B), a complete follow up of at least 12 months was available. They remained continent and continued to ful®l our prede®ned success criteria. None of these patients had any local bladder problems, especially no stone formation.
Side-eects
No patient complained of any side-eects using the intravesical application of oxybutynin in the standard dosage (A). Using escalating dosage titration (B) two of the 11 patients complained of constipation and dryness of the mouth at a dosage of 0.9 mg/kg bodyweight per day. No intravesical oxybutynin treatment had to be stopped due to side-eects.
Discussion
The pharmacokinetics of oxybutynin chloride have not been suciently delineated to explain the mechanism responsible for the eects after intravesical administration: Massad et al 17 measured plasma oxybutynin In our study, we did not measure oxybutynin plasma levels due to limited departmental funding. We focused on clinical factors such as continence situation, ecacy and side-eects of therapy. Considering side eects, Massad et al 17 and Madersbacher et al 9 described a lack of signi®cant side eects after intravesical application of oxybutynin. Green®eld et al, 11 Brendler et al 6 and Prasad et al 19 also reported no side eects. This is in contrast to Palmer et al 20 who described severe side-eects, leading to cessation of therapy, in at least 26% of their patients using a standard dosage of intravesical oxybutynin. Kaplinsky et al 12 described 25% intolerable side-eects in their meningomyelocele patients using a standard dosage of intravesical oxybutynin.
In our study we found no side-eects with the standard dosage (A). Only two of our 11 patients (18%) showed slight side-eects using the highest dosage escalation (B). Since, to the best of our knowledge, there is no other study in the literature using an equivalent dosage escalation of oxybutynin a comparison of side-eects is not possible. Our results suggest that side eects are rare even using a dosage escalation of oxybutynin. Continence rates achieved by intravesical oxybutynin therapy are discussed controversially in the literature. Buyse et al 5 reported day and night time continence in all patients, whereas Kaplinsky et al 12 found persistence of incontinence in 43% of their patients. We found day and night-time continence in 66% of our patients using a standard oxybutynin dosage (A) and in 87% of patients including the escalating dosage titration (B). Therefore we assume that there is a number of patients where the continence situation can be improved signi®cantly using a dosage escalation of intravesical oxybutynin.
In our study we describe an signi®cant improvement in urodynamic data such as age adjusted bladder capacity, maximal detrusor pressure and compliance, which is in accordance with several reports in the literature. 5 ± 7,9,11,12,18,19,21 Prasad et al 19 found an overall improvement in 88% of their patients using a standard oxybutynin dosage. In our study, an improvement rate of 87% could only be achieved using dosage escalation (B). Palmer et al 20 found that only 35% of their patients improved by the therapy.
In conclusion the intravesical application of oxybutynin is a well tolerated and ecacious therapy. The topical oxybutynin therapy using a standard dosage (0.3 mg/kg BWd) was ecient in 66% of our selected patients, very high dosages (up to 0.9 mg/kg BWd) can increase the eciency to 87% without intoxicity and slight side-eects.
